Non-invasive brain stimulation plus computer-based memory training for mild cognitive impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, controlled trial gives all participants accelerated intermittent theta burst stimulation (iTBS) over three days while randomly assigning them to active computerized cognitive training (CCT) or a sham CCT. The primary goals are to determine feasibility, acceptability, and preliminary effect sizes for combined iTBS+CCT on memory, other cognitive domains, mood, and daily function in people with MCI. Outcomes are measured with standardized neurocognitive tests, psychosocial measures, and collateral reports from a co-participant. Participants must be English-speaking adults aged 60–85 on stable medications and able to attend in-person visits at the study site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 60-85 (inclusive).
2. English as a first/primary language.
3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.
4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.
5. Meets the following requirements for current and prior medications and treatments:

   1. Is on fixed pharmacotherapy (i.e. stable dose of medication/s) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.
   2. Anti-amyloid monoclonal antibody therapy for AD/MCI:

      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.
      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.
   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.
6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).

Exclusion Criteria:

1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.
2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).
3. Daily/weekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.
4. History of significant or unstable condition/s or treatments for these condition/s that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).
5. Plan to initiate treatment for AD/MCI with monoclonal antibody therapy during study participation.
6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.
7. Current use of any implanted brain stimulation device.
8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.
9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).
10. Unable or unwilling to engage in BrainHQ activities.
11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.

Where it's running

• Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Stephanie Aghamoosa — Medical University of South Carolina
• Study coordinator: Kaitlin Cox
• Email: coxkai@musc.edu
• Phone: 843-608-1674

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Developing and testing the Liver Cirrhosis Cognitive Decline Scale (LiCCoS)

  This project will test a short questionnaire called LiCCoS to see if it can spot thinking and everyday mental problems in adults with liver cirrhosis.

  Recruiting University of Malaya · Ambāla, Haryana · NCT07418008

• Primary aldosteronism and thinking/memory problems

  This study will see if people aged 40 and older with primary aldosteronism develop memory and thinking problems over 1 to 5 years and which factors influence those changes.

  Recruiting at 2 sites Xinjiang Medical University · Chengdu, Sichuan and 1 other locations · NCT07304674

• Nutrition-based interventions to prevent cognitive decline

  This study is testing if a 6-month nutrition program can help adults at higher risk for dementia keep their thinking skills sharp.

  Recruiting at 2 sites Instituto de Saude Publica da Universidade do Porto · Porto, Portugal and 1 other locations · NCT06853405

• Using a passive home sensor to find digital signs of brain energy changes from nicotinamide riboside

  This project will try a contact-free home sensor to see if it can detect activity, sleep, and breathing changes related to nicotinamide riboside in people with mild cognitive impairment or mild Alzheimer's.

  Recruiting Mclean Hospital · Belmont, Massachusetts · NCT05245903

• Effects of Dexmedetomidine on cognitive recovery after cardiac surgery

  This study is testing if a medication called Dexmedetomidine can help people recover their thinking skills better after having heart surgery.

  Recruiting at 3 sites Phase 4 Sunnybrook Health Sciences Centre · Vancouver, British Columbia and 7 other locations · NCT04289142

• Rural Veterans and Care Partners Walking Program

  A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.

  Recruiting Creighton University · Omaha, Nebraska · NCT07914218

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.